Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.52 |
| ▸ | ARG1 | P05089 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858073 | 0.80 | GGT1 (0.50) | GGT1ARG1ARG2BLMACLY | |
| SCHEMBL636913 | 0.80 | GGT1 (0.50) | GGT1ARG1ARG2BLMACLY | |
| SCHEMBL13858056 | 0.80 | GGT1 (0.50) | GGT1ARG1ARG2BLMACLY | |
| SCHEMBL19305279 | 0.80 | GGT1 (0.50) | GGT1ARG1ARG2BLMACLY | |
| SCHEMBL8687592 | 0.80 | GGT1 (0.65) | GGT1ARG1ARG2BLMALDH1A1 | |
| SCHEMBL1012581 | 0.76 | ACLY (0.54) | ACLYALDH1A1CYP1A2ADRA1ATDP1 | |
| SCHEMBL9303118 | 0.76 | ACLY (0.39) | GGT1ACLYALDH1A1TDP1TSHR | |
| SCHEMBL2481158 | 0.76 | — | — | |
| SCHEMBL4541417 | 0.76 | GGT1 (0.31) | GGT1ACLYALDH1A1MEN1CYP1A2 | |
| SCHEMBL8688802 | 0.75 | ARG2 (0.72) | GGT1ARG1ARG2BLMACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015381-A | Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| CN-107515518-A | Annulus, image processing system and annulus unit | 富士施乐株式会社 | 2017-12-26 | — | — | CN | disclosed |
| CN-102844327-B | Template-fixed peptidomimetics with CXCR7 modulatory activity | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-102712676-B | There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-102844327-A | Template-fixed peptidomimetics with CXCR7 modulatory activity | POLYPHOR AG | 2012-12-26 | — | — | CN | disclosed |
| CN-102712676-A | Template-fixed peptidomimetics with CCR10 antagonistic activty | POLYPHOR AG | 2012-10-03 | — | — | CN | disclosed |
| CN-101203498-A | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS INC (US) | 2008-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | GGT1 1004/4885ARG1 4349/4885ARG2 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.